VKTX

Viking Therapeutics, Inc. NCM · VKTX

$37.08 +0.71 (+1.95%)

Neutral · +0.12σ

+ Compare Open in Sniper

Mkt cap $4.3B

P/E —

Day $35.29 – $37.63

52wk $25.77 – $42.79

Avg vol 2.4M

Beta 0.66

Div yld —

Next earnings —

Quick read

Plain English

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

VKTX last traded at $37.08, up 1.9% on the day; that's in the middle part of its 52-week range ($25.77–$42.79). Right now it's trading close to its recent average, with no strong stretch in either direction.

Earnings reports are the biggest scheduled catalysts to keep an eye on, and day to day, watch whether it holds above or slips below its recent average.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

above KC1 lower, +0.07 ATR from EMA21 — no notable pattern

Long —

score 16 · tech 16 / 80 · support 0 / 20

above KC1 lower, +0.07 ATR from EMA21 · no notable pattern

· Aligned with strong uptrend (strong tailwind)

How this grade was earned

total 16 pts

Cycle position 6

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

score 6 · tech 6 / 80 · support 0 / 20

below KC1 upper, +0.07 ATR from EMA21 · no notable pattern

· Counter-trend short in strong uptrend

How this grade was earned

total 6 pts

Cycle position 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

The model's verdict is “Unknown” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.

Verdict

Unknown

Accounting quality Adequate

✓ More cash than debt
✓ Current ratio 9.33 (antifragile)
✓ Debt/equity 0.12 (antifragile)

⚠ Negative retained earnings

Key statistics

All statistics →

VKTX is a $4.3 billion company, it moves more calmly than the market (beta 0.7).

Mkt cap $4.3B

P/E ttm —

Fwd P/E -8.1

Beta 0.66

Day range $35.29 – $37.63

52w range $25.77 – $42.79

Avg vol 2.4M

RSI(2) 44.9

ROE -70.0%

Net mgn —

FCF mgn —

Debt/Eq —

Div yld —

Sector Healthcare

Industry Biotechnology

Next earn —

52-week range · today's price

$25.77$42.79

More on VKTX

Earnings

See more →

Last reported: 2026-04-29
EPS (act / est): -1.37 / -0.91
Surprise: -50.5%
Next report: 2026-07-29

About

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed n…